MEXICO CITY, Sept. 14, 2021 /PRNewswire/ -- m8 Pharmaceuticals
and Biocodex have signed an exclusive licensing agreement for the
Mexican and Brazilian market for Diacomit® (stiripentol). Diacomit®
is approved for adjunctive treatment with clobazam and valproate in
Dravet syndrome in over 27 countries, including North America and Europe. Dravet syndrome, also known as severe
myoclonic epilepsy in infancy (SMEI), is a catastrophic early onset
epileptic syndrome that is thought to affect approximately 1,000 to
2,000 patients in Mexico, and
approximately 2,000 to 4,000 patients in Brazil. In most cases, the first seizures
occur during the first year of life. Dravet syndrome is
characterized by severe epilepsy, psychomotor retardation, and
often ataxia. Status epilepticus is frequent and is thought to be
in part responsible for the high premature mortality rate reported
in these patients, ranging from 15.9 to 18%.
The addition of Diacomit® to the m8 portfolio further
reinforces the company's position as a Latin American leader in the
CNS space.
"We remain committed to bringing products to Latin America. Actively partnering with
neurologists to address the unmet needs of patients and their
families, as is the case of this devastating orphan disease which
mainly affects children…" said Joel
Barlan, m8's CEO.
"We are pleased to have entered into this collaboration with m8
which is a major step forward to Diacomit development in
Latin America. With this
partnership in Mexico and
Brazil, we are aiming at providing
access to Diacomit to a large number of patients suffering from
this severe condition" adds Nicolas
Coudurier, CEO of Biocodex
About Diacomit® (stiripentol)
Diacomit® is an antiseizure medication developed by Laboratories
Biocodex. Possible mechanisms of action of its anticonvulsant
effect in humans include increase of GABAergic inhibition,
inhibition of lactate dehydrogenase and blockage of sodium and
calcium channels.Diacomit® is now approved by FDA in two
formulations (capsules and powder for oral suspension). Biocodex
received orphan-drug designation for Diacomit® from the FDA in 2008
and full approval in 2018.Diacomit® is also approved for adjunctive
treatment with clobazam and valproate in Dravet syndrome in 27
countries in the EU (January 2007),
Canada (December 2012), Japan (September
2012), Australia
(September 2019), Argentina (December
2020) and Taiwan
(June 2021).
About Biocodex
Biocodex is an independent multinational pharmaceutical company
founded in France in 1953. It is
headquartered in Gentilly (France)
with its American subsidiary in San
Mateo (CA). The company is focused on discovering,
developing and commercializing innovative therapeutics relating to
the central nervous system (epilepsy, pain management, psychiatry),
gastroenterology (microbiota) and women health.
For any information please contact:
Thomas Couroussé
Head of Neurology
division
T: +33 (0)1 41 24 46
69
t.courousse@biocodex.fr
About M8 PHARMACEUTICALS
m8 is a specialty biopharmaceutical company focused on
licensing, marketing and distributing innovative and established
therapeutics in the two largest Latin
America markets: Brazil and
Mexico. m8 aims to become the
preferred pharmaceutical partner for the licensing of high-value
innovative and proven therapies across our main therapeutic areas
CNS, Respiratory, Cardiometabolic, Rheumatology, Gastroenterology,
Onco-hematology and Orphan Diseases. m8 is a Montreux Equity
Partners portfolio company.
For more information, please
visit: www.moksha8.com
For more information please contact:
Joel Barlan
Chief Executive Officer
T: +52 (55) 4431 2933
us.wm@moksha8.com
Rafael Ferrer
Vice President of Corporate Development
T: +1 (305) 299 6998
Rafael.ferrer@moksha8.com
View original
content:https://www.prnewswire.com/news-releases/m8-pharmaceuticals-announces-license-of-exclusive-rights-for-diacomit-stiripentol-from-biocodex-sas-301376198.html
SOURCE m8 Pharmaceuticals